News: Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

157.01USD
1:44pm EDT
Change (% chg)

$-0.34 (-0.22%)
Prev Close
$157.35
Open
$156.79
Day's High
$157.97
Day's Low
$156.14
Volume
2,104,955
Avg. Vol
3,305,091
52-wk High
$173.60
52-wk Low
$114.93

Search Stocks
Select another date:

Fri, May 22 2015

Photo

Amgen ends partnership with AstraZeneca on psoriasis drug

- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

UPDATE 2-Amgen ends partnership with AstraZeneca on psoriasis drug

May 22 - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

Amgen ends collaboration with AstraZeneca on inflammation drug

May 22 - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in subjects of a trial.

Amgen first to win EU backing for new kind of cholesterol drug

- Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.

Amgen first to win EU backing for new kind of cholesterol drug

May 22 - Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.

BRIEF-EU Medicines Agency gives nod for Amgen's cholesterol drug

* Recommends approval of cholesterol drug Repatha from Amgen Inc

Amgen cholesterol drug could get EU green light this week

LONDON - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

Amgen cholesterol drug could get EU green light this week

LONDON, May 19 - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

UPDATE 1-Novartis 'biosimilar' drug blocked by U.S. appeals court

May 7 - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

FDA panel recommends approval for Amgen's skin cancer immunotherapy

- Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday.

Select another date:
Search Stocks